Sun Pharmaceutical Industries on Tuesday said it has received the US health regulator's approval to market generic version of Doxil injection, used in treating ovarian cancer, in the American market.
The Mumbai-headquartered firm in a statement said its subsidiary has received approval from the US Food and Drug Administration (USFDA) for its Doxorubicin HCl Liposome Injection.
FROM THE MAGAZINE:Cost of treatment is cancer's bigger burden
"This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC," the company said.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Shares of Sun Pharma were trading at Rs 745.70 on the Bombay Stock Exchange in afternoon trade, up 3.84 per cent from their previous close.